PP
SCLN

Paloma Partners’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Paloma Partners’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-29,188
Closed -$315K – 2405
2016
Q4 		$315K Buy
+29,188
New +$292K ﹤0.01% 1686
2016
Q3 		– Sell
-40,226
Closed -$525K – 2332
2016
Q2 		$525K Buy
+40,226
New +$527K 0.01% 1515
2014
Q3 		– Sell
-16,719
Closed -$88K – 1459
2014
Q2 		$88K Buy
+16,719
New +$81.4K ﹤0.01% 1041

Other funds holding SCLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Paloma Partners's SCLN Position: Q1 2017 in Review

Paloma Partners sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q1 2017, closing a stake of 29,188 shares — an estimated $315K sold.

Paloma Partners first reported a position in SCLN in Q2 2014 and held it in 3 quarters. The position peaked at $525K in Q2 2016. 136 funds tracked by Wall St. Rank hold SCLN as of Q1 2017.

  • Paloma Partners reported no remaining Sciclone Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • Paloma Partners sold 29,188 Sciclone Pharmaceuticals Inc shares in Q1 2017, an estimated $315K.
  • Paloma Partners first reported a position in Sciclone Pharmaceuticals Inc in Q2 2014 and held it in 3 quarters.
  • Paloma Partners's Sciclone Pharmaceuticals Inc position peaked at $525K in Q2 2016.
  • 136 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q1 2017.

Based on Paloma Partners's 13F filing for Q1 2017, filed 15 May 2017.